Atrium Therapeutics offers a rare biotech setup: a cash-rich, negative-enterprise-value precision-cardiology spinout with validated RNA-delivery technology and potentially transformative orphan-drug catalysts ahead.
Overview
Atrium Therapeutics is the newly independent precision-cardiology spinout that inherited ticker RNA after Novartis acquired Avidity for $12 billion. The company is pre-commercial and focused on targeted, non-viral RNA therapies for severe genetic cardiomyopathies. Its lead programs, ATR-1072 for PRKAG2 syndrome and ATR-1086 for PLN cardiomyopathy, aim to silence root genetic drivers in cardiac cells. Q1 2026 collaboration revenue rose sharply to $19.6 million, driven by a $15 million Bristol Myers Squibb milestone. Atrium’s core appeal is a validated delivery platform, strategic pharma backing, and a rare balance-sheet valuation disconnect.